SY-3505

· Shouyao Holdings (Beijing) Co. LTD

Drug timelines are a Plus or Pro feature.

3 regulatory and trial events tracked for SY-3505, covering 2023-02-14 to 2024-02-12. Get the full timeline:

Most recent: Clinical Trial Update: A Study Of SY-3505 Versus Crizotinib In First Line Treatment Of Patients With ALK-Positive NSCLC [Phase 3]